Lexaria Bioscience Corp.: Lexaria Announces Effective Date for Reverse Stock Split
Lexaria Bioscience Corp. (Nasdaq: LEXX) said its reverse stock split will take effect at 12:01 a.m. ET on Aug. 3, 2026, on a 1-for-15 basis, to help regain Nasdaq compliance with the $1.00 minimum bid rule. Shares will trade under LEXX with a new CUSIP. Authorized shares and convertible securities will be adjusted.
How this was made
The 30-second read
Why it matters
The reverse split (1-for-15) will consolidate shares and adjust authorized shares and convertible security terms, with the company expecting to comply in mid-August and potentially request a Nasdaq hearing if needed.
Market read
This is a scheduled corporate action with a stated compliance objective, likely driving near-term trading mechanics and volatility rather than fundamental repricing.
What to watch
Traders should monitor how options and warrants exercise prices are adjusted, and whether the company’s plan to request a Nasdaq hearing proceeds if compliance is not achieved by mid-August.
Background
Lexaria states it is performing a reverse stock split to regain Nasdaq Capital Market compliance with the $1.00 minimum bid price rule.
Ticker impact
Lexaria announces the reverse stock split effective 12:01 am ET on Aug 3, 2026, to regain Nasdaq $1.00 bid compliance.
Likely short-term volatility around Aug 3, with price action influenced by the 1-for-15 consolidation and ongoing Nasdaq compliance risk.
The filing provides the exact effective date and split ratio (1-for-15) and ties it to the Nasdaq Minimum Price Rule, but it does not provide new operating fundamentals or guidance.
Market effects
Reverse splits are common among small-cap biotech facing Nasdaq bid-price pressure; this may keep attention on listing-risk screening in the sector.
Limited, primarily affects US-listed micro/small-cap biotech liquidity and compliance sentiment.
Low; the event is company-specific and tied to Nasdaq listing rules rather than global macro or regulation.
Counterpoint
A reverse split can be viewed as a cosmetic fix that does not address underlying business drivers, so the market may discount the compliance narrative.
Key entities
- companyLexaria Bioscience Corp.
Nasdaq-listed drug delivery platform company announcing the effective date and terms of a 1-for-15 reverse stock split.
- venueNasdaq Capital Market
Listing venue whose $1.00 minimum bid price rule the company aims to satisfy.
- service_providerComputershare Trust Company of Canada
Transfer agent referenced for physical certificate holders to update records for the reverse split.
